MIRM

Companies
NASDAQ
Mirum Pharmaceuticals Inc.
Health Care
Price Chart
Overview

About MIRM

mirum pharmaceuticals, inc., a biopharmaceutical company, focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. its lead product candidate is maralixibat, an investigational oral drug that is in phase 3 clinical trial for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of alagille syndrome and biliary atresia disease. the company is also develops volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. mirum pharmaceuticals, inc. was founded in 2018 and is headquartered in foster city, california.

Market Cap
$1.2B
Volume
23.4M
Avg. Volume
21.9M
P/E Ratio
-52.11494
Dividend Yield
0.00%
Employees
231.0

Company Information

Exchange
NASDAQ
Sector
Health Care
Industry
Biotechnology
Risk & Correlation Analysis
Market Correlation
0.87
Moderate Correlation
Volatility
High (0.47)
Relative to market

Macro Factor Sensitivities

Interest Rates
Low Sensitivity
Inflation
Low Sensitivity
GDP Growth
High Sensitivity
Liquidity
High Sensitivity
Commodity Prices
Low Sensitivity
Credit Quality
High Sensitivity
Portfolio Impact
Forecasts & Predictions

Premium Forecasts

Get AI-powered price predictions, technical analysis, and market forecasts for MIRM.

1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential

Technical Analysis

Based on technical indicators and chart patterns, MIRM shows...

AI Sentiment Analysis

Market sentiment analysis indicates...

Key Statistics
Market Cap$1.2B
Volume23.4M
P/E Ratio-52.11
Dividend Yield0.00%
Important Dates
Next Dividend
Next Earnings
May 8, 2025

PortfolioPilot Analysis

Get AI-powered insights on how MIRM fits into your investment strategy and portfolio diversification.

Pricing info last updated June 18, 2025 (after market close)Other info last updated April 2, 2025